论文部分内容阅读
目的:观察恶性胸腺瘤伴重症肌无力患者的临床疗效及预后影响因素。方法:对65例恶性胸腺瘤伴重症肌无力患者进行手术治疗并辅以放疗,并按不同术式、Masaoka外科病理分期、L/B病理分型比较。结果:接受根治性手术,Masaoka外科病理分期较早的患者5、10年生存率较高(P<0.05),且前者肌无力症状改善情况亦较好(P<0.05)。不同病理(L/B)类型患者间5、10年生存率及肌无力症状改善无明显差别。结论:恶性胸腺瘤伴重症肌无力患者早期手术并辅以放疗可改善肌无力症状提高生存率;Masaoka外科病理分期和预后密切相关;L/B病理分型和重症肌无力症状的改善及预后无明显相关性。
Objective: To observe the clinical efficacy and prognostic factors of patients with malignant thymoma and myasthenia gravis. Methods: Totally 65 cases of malignant thymoma with myasthenia gravis were treated with radiotherapy and radiotherapy according to different surgical procedures, Masaoka surgical staging and L / B pathological classification. Results: The 5-year and 10-year survival rates were significantly higher in patients with Masaoka surgeries than in those with Masaoka surgeries (P <0.05), and the former had better muscle weakness (P <0.05). There was no significant difference between the 5-year and 10-year survival rates and the improvement of myasthenia gravis in patients with different pathological types (L / B). Conclusions: The early surgery of malignant thymoma with myasthenia gravis combined with radiotherapy can improve the symptoms of myasthenia gravis and improve the survival rate. The Masaoka surgical stage and prognosis are closely related to the pathological type of L / B and the improvement and prognosis of myasthenia gravis Clearly relevant.